Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.